INTRODUCING AXIAL ORTHOPAEDICS INC: A differentiated intramedullary nailing system

PRESS RELEASE 

November 27,  2023

Axial Orthopaedics Inc. offers a differentiated design of an intramedullary nailing system, targeting the complex surgeries of 1.2 million long bone fracture procedures per annum at a US market revenue spend of over $1 billion.

Innovation in trauma nailing systems has lagged behind for more than 20 years. Complex fractures often result in malalignment of long bones when using today’s systems, causing adjacent knee or ankle pain and loss of kinematic function. There is a need for a more forgiving and variable modular system to overcome post-procedural pain and associated joint problems.

Axial Orthopaedics Inc. will manufacture and distribute a new trauma technology —a modular intramedullary nailing system for long bone fracture repair— in collaboration with renowned orthopaedic surgeons in the  United States.

The Company will offer surgeons a greater choice for bone fracture alignment, reduction and healing  while offering patients relief of postoperative pain as well as significant reduction in post-operative complications. 

The benefit of the device lies in its intra-operative implant modularity and rotational capabilities for enhanced complex fracture fixation and superior procedural outcomes in comparison to technology available today. Dr. Christine Mehner, who co-designed the Axial Orthopaedics Inc.  system, commented: 

“60% of patients treated complain about postoperative pain caused by the lack of effectiveness of the implant; our objective was to  design a better solution to a common problem for enhanced procedural outcomes.”

In addition to the clinical benefits, there is a financial benefit of reduced operative time and decreased postoperative patient therapy for the hospital and payor community The Axial Orthopaedics Inc. solution is in the pre-development phase. A functioning prototype has been produced and IP has been filed via the Mayo clinic. A licensing agreement will be formed in order for Axial Orthopedics Inc. to commence proof of concept, design freeze, testing and FDA submission for clearance to market. Commercialization will then commence via an Alpha surgeon evaluation before full commercial launch. 

Discover more and join Axial Orthopaedics Inc. on its journey

Axial Orthopaedics Inc.

Craig Corrance, CEO

E:  craig.corrance@axialorthopaedics.com

W:  +1 407 923 0721

https://www.linkedin.com/in/craig-corrance-3a9736266/